CONTENT
Hengrui Pharma is a Chinese pharmaceutical company shifting from generic medicines toward self-developed innovative drugs and international partnerships. Its 2025 and 2026 disclosures show a business increasingly supported by proprietary products, substantial research investment, and overseas licensing.
The commercial interest lies in how those activities connect. Domestic medicine sales support an established operating business. Research creates new assets. Partners can contribute development capabilities and access to overseas markets. The company’s recent financial disclosures provide a useful test of how that model performs under pressure.
The clearest evidence starts with what Hengrui sells, then follows the research and contractual work behind it.
How Hengrui Pharma Is Changing Its Revenue Mix

The shift toward proprietary medicines has become measurable. Hengrui’s 2025 annual results and first-nine-months 2026 disclosure show the change:
| Share of drug sales | Full year 2025 | First nine months of 2026 |
| Innovative drugs | 58.34% | 64.59% |
| Generic medicines | 41.66% | 35.41% |
These figures compare sales composition across different reporting periods. The denominator is drug sales, which excludes licensing revenue.
Generic sales fell 16.41% year over year in the first nine months of 2026. Hengrui cited centralized procurement pressures and its decision to reduce resources allocated to that business.
The strategic reading requires care. A higher innovation share can reflect stronger proprietary products alongside a shrinking generic business. Product-level growth and commercial execution therefore deserve attention alongside the headline mix.
What Supports Jiangsu Hengrui’s Innovative Drug R&D?
Research requires sustained financial commitment. Hengrui reported 2025 R&D investment of RMB 8.72 billion [US$1.21 billion], equivalent to 27.58% of revenue.
Research Platforms Support Several Drug Types

Its 2025 annual report describes platforms spanning antibody-drug conjugates, multispecific antibodies, protein degraders, small nucleic acid drugs, and oral peptides.
A potential partner can assess a shared research capability across several candidates. That review should examine reproducibility, manufacturing requirements, and the quality of evidence each platform produces.
The 2025 results also show that oncology supplied most innovative medicine revenue. The broader research agenda introduces a transfer question: which teams, production processes, and clinical relationships can support another therapeutic area, and which capabilities need additional investment?
Clinical Differentiation Matters
In an October 2026 Fierce Biotech interview, R&D leader Lianshan Zhang described a strategy centered on fast follow-on development with clinically meaningful differentiation, alongside work on first-in-class candidates.
This distinction sharpens the evaluation of innovative drugs. A proprietary molecule can address an established target. Its competitive case still needs a clear patient benefit, such as addressing resistance or helping patients whom existing regimens serve poorly.
How the Hengrui GSK Agreement Shares Development Work
The July 2025 GSK agreement illustrates how Hengrui’s research capabilities can become a contracted development relationship.
One Licensed Asset and Eleven Additional Options

The arrangement covers HRS-9821, a PDE3/4 inhibitor under development for chronic obstructive pulmonary disease, plus options on eleven additional programs across respiratory disease, immunology, inflammation, and oncology.
Hengrui leads those additional programs through Phase 1, including patients outside China. GSK can exercise its development and commercialization options after Phase 1, or earlier at its election.
GSK agreed to US $500million inup front fees.Approximately US$12 billion in potential future milestones, depending on all programs being optioned and all relevant milestones being achieved. Royalties provide a further potential income stream.
The structure gives both sides staged decisions. Hengrui must deliver early clinical development; GSK can select programs as evidence develops. Commercially, this rewards reliable research execution and clear handoffs between organizations. The next useful signal is an option exercise or a completed development milestone, each tied to a specific program.
What Hengrui’s GLP-1 Pipeline Actually Contains

Hengrui’s metabolic portfolio contains different molecules, formulations, and regional development plans. The programs below should receive separate assessments.
| Program | Form and mechanism | Latest cited 2026 development milestone |
| HRS-7535, also called KAI-7535 | Oral small-molecule GLP-1 receptor agonist | China accepted applications for type 2 diabetes and weight management, according to the October quarterly filing |
| Ribupatide, also called HRS9531 or KAI-9531 | Once-weekly injectable GLP-1/GIP dual agonist | Kailera completed enrollment in its global Phase 3 KaiNETIC program in September |
| HRS-1596 | Oral GLP-1/GIP dual agonist with potential weekly dosing | Phase 1-ready when Novo Nordisk announced its September agreement |
Kailera’s July 2026 update described a global Phase 2 KAI-7535 trial testing dose selection and gradual dose escalation, alongside Hengrui’s China Phase 3 results. China’s later filing milestone therefore does not establish equivalent progress overseas.
Kailera expects KaiNETIC topline results in mid-2028, according to its September update. That timetable matters when assessing the commercial opportunity: completing enrollment leaves a substantial period for treatment, analysis, and possible regulatory work before any potential launch.
Novo’s HRS-1596 agreement has a potential total value of up to US$2.6 billion, including US$300 million upfront and milestone-dependent payments, plus potential royalties. The September announcement is expected to close in the fourth quarter of 2026. Weekly oral dosing remains a development goal for an early-stage candidate.
How BMS Expands the International Partnership Model
The May 2026 Bristol Myers Squibb collaboration involves thirteen programs: four Hengrui oncology and hematology assets, four BMS immunology assets, and five programs for joint discovery and development.
Hengrui also has options to co-develop selected assets and potentially conduct certain commercialization activities globally. This creates opportunities to participate in additional development and commercial work.
Territorial definitions deserve close reading. GSK’s excluded territory includes mainland China, Hong Kong, Macau, and Taiwan. BMS defines the retained Hengrui territory as mainland China, Hong Kong, and Macau. A company-level partnership label cannot substitute for an asset-by-asset rights review.
For businesses assessing Chinese research partners, this is a practical lesson: evaluate the responsibilities, capabilities, and territories attached to each program.
A review should also establish who controls development decisions, funds additional trial work, and owns intellectual property generated through joint research. Clear answers help both organizations plan for study changes, delays, and additional costs before those issues affect execution.
What Will Test Hengrui’s Commercial Progress?
Cash Receipts and Recognized Revenue Answer Different Questions
Hengrui Pharmaceuticals reported nine-month 2026 licensing revenue of RMB 2.781 billion (approximately US$417 million). Its quarterly filing ties revenue recognition partly to fulfillment of contractual obligations.
A review should distinguish contract value, cash received, and accounting revenue. Each measures a different part of the transaction.
Hospital Access Remains a Commercial Constraint
The same filing warned that innovative medicine sales growth had fallen below initial expectations, citing slower hospital access and stronger competition for certain established products.
A practical assessment should track hospital entry, realized product sales, and overseas trial progress. These indicators connect research output to commercial performance and reveal where further investment or a different operating approach may be needed.
Explore China’s Innovation Models With ChoZan
Hengrui Pharma raises useful questions about how Chinese companies build research capabilities and structure global cooperation. ChoZan, founded by Ashley Dudarenok, helps businesses investigate China through tailored research, expert dialogues, learning expeditions, and strategy workshops.
Start with a specific question about your sector, competitive position, or innovation model.
Book a consultation to discuss a focused research or learning brief.
Hengrui Pharma FAQs
What Is Hengrui Medicine’s Official English Name?
The company uses Hengrui Pharma as its English brand and Jiangsu Hengrui Pharmaceuticals Co., Ltd. as its legal name. Use that legal name, its Chinese identity 恒瑞医药, and the published stock codes when verifying corporate materials or partner announcements.
Where Is Jiangsu Hengrui Pharmaceuticals Headquartered?
The company lists its headquarters in Lianyungang, Jiangsu province. Its annual report separately identifies its registered office and Hong Kong business address. Those distinctions help when checking corporate records, arranging business correspondence, or verifying a contracting entity.
Is Hengrui Pharma Publicly Listed?
Yes. Hengrui trades under stock code 600276 in Shanghai and 01276 in Hong Kong. Its Hong Kong shares began trading on May 23, 2025. Check the exchange and share class when comparing prices, ownership disclosures, or trading information.
Does Hengrui Use AI in Drug Discovery?
Yes. Its 2025 annual report describes the Hengrui-LingShu and bioinformatics platforms for molecular design, drug-property prediction, and optimization. These are reported research applications. Any claim about quantified time or cost savings requires separate supporting evidence.
What Is Hengrui’s NewCo Model?
A NewCo is a separately financed company that develops licensed assets. Hengrui’s September 2025 Braveheart Bio agreement combined a drug license with cash and equity consideration. This structure can give Hengrui financial participation in the partner company’s development.
What Did Hengrui Announce About Fuzuloparib in Europe?
On October 8, 2026, Hengrui announced EMA validation of an application for Wevdury, its fuzuloparib product, in combination for prostate cancer. This was an application milestone. Check subsequent regulatory decisions before treating the announcement as evidence of European authorization.
Where Can I Find Hengrui GLP-1 Clinical Trials?
Start with the developer’s official trial page, then follow its ClinicalTrials.gov links. Kailera lists its KaiNETIC studies and trial identifiers. Before contacting a study site about participation, check each record’s sponsor, recruitment status, locations, and eligibility criteria.
Why Can Hengrui Trials Report Different Weight-Loss Figures?
Different analysis methods can produce different results within the same trial. Kailera’s July 2026 HRS-7535 update reports efficacy and treatment-policy estimates separately. Compare the dose, time point, patient population, and how treatment discontinuation is handled before interpreting percentages.
Where Can I Find Hengrui China Company Filings?
Use the company’s Chinese investor relations pages and exchange announcements. Match the reporting period and legal entity, then check the original filing when an English summary omits detail. Preserve the publication date when sharing or comparing disclosures.
How Did Hengrui Allocate Its Hong Kong IPO Proceeds?
Its 2025 annual report allocates 45% to clinical studies, 20% to new drug development, 10% to global acquisitions and collaborations, 15% to production and R&D facilities, and 10% to working capital and general corporate purposes.
Join Thousands Of Professionals
By subscribing to Ashley Dudarenok’s China Newsletter, you’ll join a global community of professionals who rely on her insights to navigate the complexities of China’s dynamic market.
Don’t miss out—subscribe today and start learning for China and from China!
Latest posts
About The Author
Ashley Dudarenok
Ashley Dudarenok is a leading expert on China’s digital economy, a serial entrepreneur, and the author of 11 books on digital China. Recognized by Thinkers50 as a “Guru on fast-evolving trends in China” and named one of the world’s top 30 internet marketers by Global Gurus, Ashley is a trailblazer in helping global businesses navigate and succeed in one of the world’s most dynamic markets.
She is the founder of ChoZan 超赞, a consultancy specializing in China research and digital transformation, and Alarice, a digital marketing agency that helps international brands grow in China. Through research, consulting, and bespoke learning expeditions, Ashley and her team empower the world’s top companies to learn from China’s unparalleled innovation and apply these insights to their global strategies.
A sought-after keynote speaker, Ashley has delivered tailored presentations on customer centricity, the future of retail, and technology-driven transformation for leading brands like Coca-Cola, Disney, and 3M. Her expertise has been featured in major media outlets, including the BBC, Forbes, Bloomberg, and SCMP, making her one of the most recognized voices on China’s digital landscape.
With over 500,000 followers across platforms like LinkedIn and YouTube, Ashley shares daily insights into China’s cutting-edge consumer trends and digital innovation, inspiring professionals worldwide to think bigger, adapt faster, and innovate smarter.
READ MORE RELATED POSTS


